TP wnt inhibitor - JW Pharmaceuticals
Alternative Names: TP Wnt inhibitor-JW PharmaceuticalsLatest Information Update: 18 Jul 2025
At a glance
- Originator JW Pharmaceutical
- Class Cardiovascular therapies
- Mechanism of Action Wnt protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Cardiovascular disorders; Metabolic disorders
Most Recent Events
- 02 Jul 2025 Preclinical trials in Cardiovascular disorders in South Korea (unspecified route) (JW Pharmaceuticals pipeline, July 2025)
- 02 Jul 2025 Preclinical trials in Metabolic disorders in South Korea (unspecified route) (JW Pharmaceuticals pipeline, July 2025)